Controlled Release Injection of a Central Nervous System Acting Drug

by Ibrahim Elsayed

Alzheimer’s disease is a chronic, progressive, neurodegenerative disorder of the brain characterized by deficits in memory and cognitive function. Donepezil is a reversible, noncompetitive cholinesterase inhibitor. It has a high binding specificity for brain acetylcholinesterase, with little to no affinity for butyrylcholinesterase. It is approved by the FDA for the treatment of severe Alzheimer’s disease. The aim of this work is to formulate depot injection lipospheres and in situ implants containing Donepezil for treatment of Alzheimer disease in order to decrease dosing frequency and increase patient compliance. The work is divided Chapter 1: Formulation and In Vitro Evaluation of Injectable Donepezil Lipospheres. Chapter 2: Formulation and In Vitro Evaluation of Injectable Donepezil in Situ Implant. Chapter 3: Comparative Pharmacokinetic Study of Different Injectable Donepezil Formulae.

292 pages, Paperback

Published November 6, 2014

About the author

إبراهيم السيد يوسف
روائى شاب من مواليد محافظة القاهرة

فى 21 / 8 / 1992
تخرج فى كلية الهندسة جامعة القاهرة سنة 2014
الصفحة الرسمية على الفيس بوك :
https://www.facebook.com/ibrahim.elsa...
نُشر له أول رواية طويلة بعنوان " فينوس " عن دار ليليت